Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Melanotan-1 Injectable vs Oral: Comparison

The choice between injectable and oral Melanotan-1 isn't a trade-off—it's a distinction between a functional delivery method and a non-functional one. Bioavailability 95–100%. Peptide enters circulation intact <0.1%. Complete proteolytic degradation before abs

This comparison does not assign a generated winner or score.

  • The choice between injectable and oral Melanotan-1 isn't a trade-off—it's a distinction between a functional delivery method and a non-functional one.
  • Bioavailability
  • 95–100%. Peptide enters circulation intact
  • <0.1%. Complete proteolytic degradation before absorption
  • Injectable is the only validated route; oral forms achieve unmeasurable plasma concentrations
  • Onset of Action
  • 48–72 hours to visible pigmentation increase
  • No measurable effect at any dose tested
  • Subcutaneous administration is the only method producing MC1R activation
  • Half-Life
  • 1.5–2.5 hours plasma half-life; melanogenesis persists 7–10 days
  • N/A. No systemic exposure
  • Injectable formulations maintain therapeutic effect for one week per dose
  • Enzymatic Stability
  • Bypasses GI proteases entirely; reaches receptors intact
  • Degraded by pepsin, trypsin, chymotrypsin within 20–30 minutes
  • Digestive enzymes render oral peptides biologically inert
  • FDA-Approved Formulation
  • Scenesse (afamelanotide implant, 16mg controlled-release)
  • None. No oral Melanotan-1 product has FDA approval
  • Regulatory approval only exists for injectable/implant routes
  • Cost per Dose
  • Research-grade vials $40–$80 per 10mg (5–10 doses depending on protocol)
  • Variable, but irrelevant—oral forms produce no effect
  • Price comparison is moot when oral administration fails pharmacokinetically
  • This table underscores a fundamental principle: peptide structure dictates delivery method. Melanotan-1's amino acid sequence cannot be altered without destroying MC1R binding affinity, and that sequence cannot survive oral administration without carrier technology that doesn't yet exist for this compound.
More references

Related material